ReviewFrontiers in medicine2021
TGF-β1 Signaling: Immune Dynamics of Chronic Kidney Diseases.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 56 citations in OpenAlex.
- Transforming growth factor-β in kidney disease in dogs and cats: a review of the evidence of its role in renal fibrosis.Journal of veterinary internal medicine · 2026Review
- Effects of Amaranthus spinosus Extract and Its Polyphenol Rich Fraction in Adenine-Induced Chronic Kidney Disease in Experimental Animals.Chemistry & biodiversity · 2026Article
- Stage-wise variation in serum C-reactive protein and cardiovascular risk in chronic kidney disease of uncertain etiology among Sri Lankans; a preliminary study.BMC research notes · 2026Article
- The core mechanism of hypertension-linked renal fibrosis: "RAAS-ROS-inflammation-fibrosis" axis.iScience · 2026Review
- Visnagin attenuates thioacetamide-induced kidney damage through suppression of renal injury marker, oxidative stress, inflammation, apoptosis, and TGF-β-mediated renal fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- TGF-β1 Gene Polymorphisms in Saudi Patients With Type 2 Diabetes With or Without Diabetic Nephropathy.International journal of endocrinology · 2026Article
- Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis.JCI insight · 2025Article
- Cystic fibrosis-related kidney disease-emerging morbidity and disease modifier.Pediatric nephrology (Berlin, Germany) · 2025Review
- Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD).Journal of clinical medicine · 2025Review
- Short-term effect of atorvastatin on renal oxidative stress, inflammation, and fibrosis in a rat model of streptozotocin-induced diabetes.Journal of diabetes and metabolic disorders · 2025Article
- The key role of miR‑378 in kidney diseases (Review).Molecular medicine reports · 2025Review
- Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy.International journal of biological sciences · 2025Review
- Article
- Macrophage-myofibroblast transition as a novel therapeutic target in shoulder stiffness: multi-omics study and experimental validation.Frontiers in cell and developmental biology · 2025Article
- Artesunate alleviates kidney fibrosis by restoring klotho protein and suppressing Wnt/β-catenin signalling pathway.Frontiers in cell and developmental biology · 2025Article
- Personalized Antifibrotic Therapy in CKD Progression.Journal of personalized medicine · 2024Review
- Myofibroblast-derived exosomes enhance macrophages to myofibroblasts transition and kidney fibrosis.Renal failure · 2024Article
- Urolithin A Ameliorates the TGF Beta-Dependent Impairment of Podocytes Exposed to High Glucose.Journal of personalized medicine · 2024Article
- Research progress on miR-124-3p in the field of kidney disease.BMC nephrology · 2024Review
- Targeting the nuclear long noncoding transcript LSP1P5 abrogates extracellular matrix deposition by trans-upregulating CEBPA in keloids.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a major cause of morbidity and mortality worldwide, imposing a great burden on the healthcare system. Regrettably, effective CKD therapeutic strategies are yet available due to their elusive pathogenic mechanisms. CKD is featured by progressive inflammation and fibrosis associated with immune cell dysfunction, leading to the formation of an inflammatory microenvironment, which ultimately exacerbating renal fibrosis. Transforming growth factor β1 (TGF-β1) is an indispensable immunoregulator promoting CKD progression by controlling the activation, proliferation, and apoptosis of immunocytes via both canonical and non-canonical pathways. More importantly, recent studies have uncovered a new mechanism of TGF-β1 for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.